Exchange: NASDAQ·Updated 01:46 PM EDT
News
all
press releases
Are Options Traders Betting on a Big Move in AtriCure Stock?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Zacks
More News
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCures...
Business Wire
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzingaread more...
Benzinga
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of +500.00% and +1.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AtriCure Reports Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. Our team delivered healthy growth and a...
Business Wire
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23...
Business Wire
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Zacks
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global...
Business Wire
<
1
2
>

Advertisement|Remove ads.